Quote | Praxis Precision Medicines Inc. (NASDAQ:PRAX)
Last: | $52.40 |
---|---|
Change Percent: | 0.75% |
Open: | $52.75 |
Close: | $52.40 |
High: | $54.37 |
Low: | $51.665 |
Volume: | 158,072 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
News | Praxis Precision Medicines Inc. (NASDAQ:PRAX)
2024-04-26 16:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...
Message Board Posts | Praxis Precision Medicines Inc. (NASDAQ:PRAX)
Subject | By | Source | When |
---|---|---|---|
Despite Trial Failure Praxis Still Seeks Advancing Essential | ctb | investorshub | 03/03/2023 4:15:45 PM |
News today. | IPO$ | investorshub | 03/03/2023 4:14:25 PM |
Not looking good now. | IPO$ | investorshub | 03/03/2023 4:13:49 PM |
Getting killed this am. | IPO$ | investorshub | 03/03/2023 3:19:59 PM |
FDA phase 2 approval due in next week | IPO$ | investorshub | 03/01/2023 8:31:53 PM |
News, Short Squeeze, Breakout and More Instantly...
Praxis Precision Medicines Inc. Company Name:
PRAX Stock Symbol:
NASDAQ Market:
2024-04-26 16:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translatin...
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imb...